Recombinant Mouse Myotonin-protein kinase (Dmpk)

Advanced Research Questions

• How can recombinant mouse Dmpk be used to study myotonic dystrophy pathophysiology?

Recombinant mouse Dmpk serves as a valuable tool for investigating myotonic dystrophy type 1 (DM1) pathophysiology through several methodological approaches:

• Functional studies of normal Dmpk activity:

  • In vitro kinase assays to identify and characterize physiological substrates

  • Structure-function analyses to understand how Dmpk regulates calcium homeostasis

  • Cellular localization studies to determine compartment-specific functions

• Comparison with mouse models of DM1:
  Multiple mouse models have been developed, each offering unique insights:

  • DMSXL mice (>1000 CTG repeats): Show multisystemic phenotypes including reduced muscle strength, peripheral neuropathy, respiratory impairment, and cardiac conduction defects

  • EpA960 mice: Feature inducible expression of large, interrupted CTG repeats causing cardiac, muscular, and neurological phenotypes

  • HSAlr mice: Express CTG repeats specifically in skeletal muscles, developing myotonia that can be quantified by electromyography (EMG)

• Investigation of toxic RNA mechanisms:

  • RNA-FISH combined with MBNL1 immunostaining to visualize and quantify toxic RNA foci

  • Assessment of alternative splicing patterns of known MBNL1-regulated transcripts

  • Gene expression profiling by RNA sequencing to identify dysregulated pathways

These approaches allow researchers to distinguish between loss-of-function effects (reduced DMPK activity) and toxic RNA gain-of-function effects, providing a comprehensive understanding of DM1 pathophysiology.

• What methodologies are most effective for assessing Dmpk kinase activity in vitro?

Several methodologies can be employed to assess the kinase activity of recombinant mouse Dmpk, each with specific advantages:

• Radioactive kinase assays:

  • Incubation of recombinant Dmpk with substrate proteins and [γ-32P]ATP

  • Measurement of 32P incorporation into substrates by scintillation counting or autoradiography

  • Quantification using phosphorimaging technology

• Non-radioactive assays:

  • ADP-Glo™ or similar assays measuring ADP production during phosphorylation

  • ELISA-based assays using phospho-specific antibodies

  • Fluorescence resonance energy transfer (FRET)-based assays

• Substrate-specific assays:
  The following physiologically relevant substrates can be used:

  • Phospholamban (PLN): A regulator of calcium pumps in myocytes

  • FXYD1/PLM: Induces chloride currents when phosphorylated

  • PPP1R12A: When phosphorylated by Dmpk, inhibits myosin phosphatase activity

For all assays, appropriate controls should include:

• Kinase-dead Dmpk mutants (typically K100A or similar)

• Specific Dmpk inhibitors (if available)

• Absence of ATP or substrate as negative controls

• How can CRISPR interference be applied to study Dmpk function in cellular and mouse models?

CRISPR interference (CRISPRi) has emerged as a powerful tool for studying Dmpk function by enabling precise transcriptional repression. A methodological approach includes:

• Design of sgRNAs targeting the Dmpk promoter:

  • Multiple sgRNAs should be designed and tested for efficiency

  • In a study targeting human DMPK, guides targeting the promoter achieved up to 80% reduction in transcript levels

• CRISPRi system components:

  • dCas9 fused to a KRAB repressor domain

  • sgRNA expression cassette

  • Appropriate selection markers for stable integration

• Delivery methods:

  • Lentiviral vectors for cell culture studies

  • AAV vectors for in vivo applications in mouse models

  • Transgenic mouse generation for constitutive or inducible expression

• Assessment of Dmpk knockdown effects:

  • Quantification of Dmpk transcript levels by qRT-PCR

  • Western blot analysis of Dmpk protein expression

  • Evaluation of downstream effects on:

    • Alternative splicing patterns

    • Gene expression profiles

    • Cellular electrophysiology (membrane resistance measurements)

This approach was successfully used in DM1 patient-derived cells, where DMPK promoter targeting by CRISPRi reduced toxic CUGexp-DMPK transcripts by 80% and normalized cellular electrophysiological parameters .

• What are the differences between various mouse models used to study Dmpk function and DM1 pathology?

Several mouse models have been developed to study Dmpk function and DM1, each with distinct characteristics:

Each model offers unique advantages and limitations:

• DMSXL mice provide the most comprehensive model but with variable penetrance

• EpA960 mice allow temporal control of disease induction

• HSAlr mice focus on muscle-specific effects, ideal for myotonia studies

• Knockout models isolate Dmpk loss-of-function effects from toxic RNA effects

These models have contributed significantly to understanding disease mechanisms and testing therapeutic approaches, although none perfectly recapitulates all aspects of human DM1.

• What therapeutic strategies targeting Dmpk or CUG repeat expansions are currently being investigated?

Multiple therapeutic strategies targeting Dmpk expression or CUG repeat toxicity are under investigation:

• CRISPR interference targeting the DMPK promoter:

  • Uses nuclease-dead Cas9 (dCas9) fused to KRAB repressor domain

  • sgRNAs targeting the DMPK promoter achieved 80% reduction in toxic transcripts

  • Normalized cellular electrophysiological defects in DM1 cells

  • Improved alternative splicing patterns

• U7 small nuclear RNA (snRNA) approach:

  • Modified U7snRNAs containing antisense sequences targeting the 3'UTR region

  • Delivers steric hindrance to CUG repeats

  • When delivered via AAV1 to HSAlr mice:

    • Reduced mechanical myotonia

    • Eliminated electrical myotonia in some muscles

    • Decreased number and intensity of RNA foci

    • Improved splicing of Serca1 and Clcn1 genes

• Antisense oligonucleotides (ASOs):

  • Binds to CUG repeats or targets DMPK mRNA for degradation

  • Limitation: Requires repeated injections for sustained effect

• AAV-based approaches:

  • Provides longer-term expression of therapeutic constructs

  • Various delivery vectors including AAV1 have been tested

  • Potential for sustained correction of disease phenotypes

Each approach has advantages and limitations regarding specificity, efficacy, delivery challenges, and duration of effect. The most promising strategies may involve combinations of these approaches or tissue-specific targeting.

• How can transcriptomic analysis be used to evaluate the effectiveness of Dmpk-targeting therapies?

Transcriptomic analysis provides critical insights into the effectiveness of Dmpk-targeting therapies through comprehensive assessment of gene expression and splicing changes:

• RNA sequencing methodology:

  • Paired-end deep RNA sequencing (>80M reads/sample)

  • Multiple biological replicates (4+ recommended)

  • Comparison between treated DM1 cells/tissues, untreated DM1, and wild-type controls

• Alternative splicing analysis:

  • Detection of splicing events with defined thresholds (e.g., FDR ≤ 0.05; ΔPSI ≥ |0.15|)

  • In one study, 2,432 unique splicing events were identified in DM1 cells versus controls

  • Effective DMPK inhibition corrected approximately 75% of these events

• Gene expression analysis:

  • Identification of differentially expressed genes (e.g., FDR ≤ 0.05; log2 FC ≥ |1|)

  • Assessment of patterns returning toward wild-type profiles

  • Gene ontology enrichment analysis to identify functional categories of restored genes

• Validation of key splicing events:

  • RT-PCR confirmation of critical splicing changes in:

    • MBNL1-regulated transcripts (e.g., Serca1, Clcn1)

    • Transcripts linked to disease symptoms (e.g., cardiac, muscle, neurological)

  • Correlation with functional improvements

For example, DMPK promoter silencing using CRISPRi normalized gene expression patterns related to cellular ionic currents, which correlated with improved electrophysiological parameters measured by whole-cell patch clamp .

• What techniques are used to evaluate the functional effects of Dmpk-targeting therapies in cellular and animal models?

Evaluation of Dmpk-targeting therapies requires multi-dimensional assessment of molecular, cellular, and physiological parameters:

• Molecular assessments:

  • RNA-FISH combined with MBNL1 immunostaining to quantify:

    • Number and intensity of CUGexp RNA foci

    • MBNL1 sequestration and localization

  • RT-PCR and RNA sequencing to evaluate:

    • DMPK transcript levels

    • Alternative splicing correction

    • Global gene expression changes

• Cellular functional assays:

  • Electrophysiological measurements:

    • Whole-cell patch clamp to assess membrane resistance (Rm)

    • In one study, DMPK silencing normalized Rm in DM1 cells to wild-type levels

  • Calcium handling assays:

    • Calcium imaging to assess sarcoplasmic reticulum function

    • Contractility measurements in isolated cardiomyocytes

• In vivo functional assessments:

  • Electromyography (EMG) to quantify myotonia:

    • Measures both mechanical and electrical myotonia

    • U7snRNA therapy in HSAlr mice reduced mechanical myotonia and eliminated electrical myotonia in some muscles

  • Muscle strength testing:

    • Grip strength measurements

    • Running wheel or treadmill performance

  • Cardiac conduction testing:

    • Electrocardiography (ECG) parameters

    • Heart rate variability analysis

• Histological analyses:

  • Muscle histology to assess:

    • Fiber type distribution

    • Central nucleation

    • Fibrotic changes

  • Immunohistochemistry for DMPK and MBNL1 localization

These multi-level assessments provide comprehensive evaluation of therapeutic efficacy, connecting molecular corrections to functional improvements at the physiological level.

Methodology for Model Systems

• What expression vectors and purification strategies are optimal for obtaining high-yield, functional recombinant mouse Dmpk?

Optimizing expression and purification of recombinant mouse Dmpk requires careful consideration of vectors, expression conditions, and purification strategies:

Expression Vectors:

• Bacterial expression:

  • pET series vectors (especially pET28a) with N-terminal His-tag

  • pGEX vectors for GST-fusion proteins to enhance solubility

  • pMAL vectors for MBP-fusion proteins to further improve solubility

• Mammalian expression:

  • pcDNA3.1 for transient expression

  • pLenti vectors for stable cell line generation

  • Inducible expression systems (Tet-On/Off) to control expression levels

Expression Conditions:

Purification Strategy:

• For His-tagged Dmpk:

  • IMAC (Ni-NTA or Co-NTA) chromatography

  • Buffer containing 20-50 mM imidazole to reduce non-specific binding

  • Elution with 250-500 mM imidazole gradient

• Additional purification steps:

  • Ion exchange chromatography (IEX)

  • Size exclusion chromatography (SEC)

  • Affinity chromatography with ATP-agarose for enrichment of active kinase

Critical Considerations:

• Include protease inhibitors throughout purification

• Maintain 5-10% glycerol in buffers to enhance stability

• Add reducing agents (DTT or β-mercaptoethanol) to prevent oxidation

• For E. coli expression, consider using specialized strains (Rosetta, Arctic Express) to enhance correct folding

• How can researchers develop and validate Dmpk kinase assays for drug screening applications?

Developing robust Dmpk kinase assays for drug screening requires careful optimization and validation:

Assay Development:

• Selection of appropriate assay format:

  • Radiometric assays: Gold standard for sensitivity but limited throughput

  • Fluorescence-based assays: FRET or TR-FRET for high-throughput screening

  • Luminescence-based assays: ADP-Glo™ for ATP consumption measurement

  • AlphaScreen® technology: For no-wash, homogeneous format

• Substrate selection:

  • Validated physiological substrates: Phospholamban (PLN), FXYD1/PLM

  • Synthetic peptides derived from known substrates

  • Generic kinase substrates for initial screening

• Assay optimization parameters:

  • Enzyme concentration: Determine linear range of activity

  • ATP concentration: Use Km value for ATP for inhibitor screening

  • Incubation time: Establish linear reaction phase

  • Buffer composition: Optimize salt, pH, and divalent cations

  • DMSO tolerance: Typically test up to 5% DMSO

Assay Validation:

• Statistical validation:

  • Z' factor determination (>0.5 considered excellent)

  • Signal-to-background ratio (>3 recommended)

  • Coefficient of variation (<10% ideal)

• Control compounds:

  • Staurosporine as broad-spectrum kinase inhibitor

  • ATP-competitive inhibitors

  • Specific Dmpk inhibitors (if available)

• Orthogonal assays:

  • Cellular assays measuring Dmpk substrate phosphorylation

  • Biophysical binding assays (thermal shift, SPR)

  • ATP competition assays to determine mechanism of action

• Counter-screens:

  • Related kinases to assess selectivity

  • ATP-binding proteins to eliminate non-specific binders

  • Cytotoxicity assays to identify generally toxic compounds